Home » Stocks » INAB

IN8bio, Inc. (INAB)

IN8bio will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 14.75M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

IN8bio, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

5 days ago - SEC

IN8bio has trod an unusual path to an IPO but now has revived its once-dropped attempt.

1 month ago - FierceBiotech

About INAB

IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct... [Read more...]

IPO Date
Pending
Stock Exchange
NYSE
Ticker Symbol
INAB
Full Company Profile